CopyFind

ACICLOVIR CINFA 200 MG COMPRIMIDOS EFG

Analogs of ACICLOVIR CINFA 200 MG COMPRIMIDOS EFG

Find cheaper analogs and generic equivalents for ACICLOVIR CINFA 200 MG COMPRIMIDOS EFG.

Ingredients

Active Ingredient: aciclovir


Product Overview

About ACICLOVIR CINFA 200 MG COMPRIMIDOS EFG

ACICLOVIR CINFA 200 MG COMPRIMIDOS EFG is a pharmaceutical product formulated for the treatment of viral infections caused by the herpes simplex virus. This medicine is presented in tablet form and is classified as an antiviral agent. It is designed to be taken orally to help manage specific viral conditions by inhibiting the replication of the virus within the body. Patients should always follow the specific dosage instructions provided by their healthcare professional or as indicated on the package insert to ensure the medication is used safely and effectively. This product is an EFG (Equivalente Farmacéutico Genérico) medicine, meaning it meets the same quality, safety, and efficacy standards as the reference product.

Key Benefits & Uses

  • Used for the treatment of herpes simplex virus infections of the skin and mucous membranes.
  • Effective in the management of initial and recurrent genital herpes infections.
  • Helps in the suppression of recurrent herpes simplex infections in immunocompetent patients.

Active Ingredient & Action

The active ingredient in this medicine is aciclovir. Aciclovir works by interfering with the DNA synthesis of the herpes virus, which prevents the virus from multiplying and spreading further throughout the body. By targeting the viral enzymes, it helps the immune system control the infection more efficiently.

Important Notes

This medicine should only be used under the supervision of a doctor. Consult your pharmacist or physician regarding potential interactions with other medications or specific health conditions. Keep this product out of the reach and sight of children at all times.

Visitor ratings

Help others by rating how useful this product page is.

No ratings yet — be the first.